William Alazawi

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts

M Alexander, A. Katrina Loomis, Johan van der Lei et al. · BMC Medicine · 2019 · 291 citations · Full text

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2

Alastair O’Brien, James N. Fullerton, Karen A. Massey et al. · Nature Medicine · 2014 · 282 citations · Full text

Inflammation, Prostaglandin E2, Autoimmune Disease +15

Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease

M Alexander, A. Katrina Loomis, Jolyon Fairburn-Beech et al. · BMC Medicine · 2018 · 262 citations · Full text